Navigation Links
European Authorities Approve New Manufacturing Facility for Shire's REPLAGAL® (agalsidase alfa)
Date:6/24/2011

DUBLIN and LEXINGTON, Massachusetts, June 24, 2011 /PRNewswire/ --


 

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the European Medicines Agency has approved the purification of REPLAGAL® (agalsidase alfa) drug substance at its new manufacturing facility in Lexington, MA, US.  REPLAGAL, Shire's enzyme replacement therapy for the treatment of Fabry disease is the first product that will be made available to patients from the new facility.

With this approval, the company now has two approved facilities - Alewife, which is located in Cambridge, MA, as well as the new Lexington facility - in which to purify REPLAGAL, thus providing increased manufacturing flexibility. The cell culture portion of the REPLAGAL manufacturing process will continue to be conducted at Alewife.

 "We are pleased that we were able to accelerate the construction and approval of our new manufacturing facility in order to provide rapid access to important therapies for patients in need," said Bill Ciambrone, Senior Vice President of Technical Operations, Shire HGT. "This new facility allows greater flexibility to meet global demand for our products, including REPLAGAL."

Shire reiterated that it has sufficient product inventory to continue to meet the needs of Fabry patients worldwide currently receiving REPLAGAL and that it can meet anticipated additional demand.  The Company is committed to continuing to provide uninterrupted long-term access to the product at the licensed dose.  

In addition to REPLAGAL, Shire anticipates regulatory agency submission of the VPRIV (velaglucerase alfa) manufacturing process at the new Lexington manufacturing facility by the end of 2011.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFEHARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

For further information please contact:



    Investor Relations 

    Eric Rojas (erojas@shire.com)          +1-781-482-0999
    Sarah Elton-Farr                       +44-1256-894-157
    (seltonfarr@shire.com)

    Media              

    Jessica Mann (jmann@shire.com)         +44-1256-894-280
    Jessica Cotrone (jcotrone@shire.com)   +1-781-482-9538

 


'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... -- Stock-Callers.com navigates the Medical Instruments and Supplies ... of non-electronic medical, surgical, dental, and veterinary instruments and apparatus. ... Dickinson and Co. (NYSE: BDX), Antares Pharma Inc. (NASDAQ: ATRS), ... Download the free research reports on these stocks today: ... http://stock-callers.com/registration ...
(Date:3/30/2017)... 2017 The topical drug delivery market ... 2016, growing at a CAGR of 6.4% from 2016 to ... major end-user in market. While North America ... ... tables and 41 figures, 10 Company profiles spread across 144 ...
(Date:3/30/2017)... -- Lannett Company, Inc. (NYSE: LCI ) today ... payment against its existing revolving credit facility. ... million payment we made earlier this year in January, ... interest expense, at current rates" said Arthur Bedrosian ... solid and we continue to generate strong cash flows, ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 , ... In the United ... 300,000 people each year develop other types of metastatic brain tumors(3). Though most meningiomas ... brain(3). As efforts focus on finding more effective treatment options, the San Diego ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered ... feedback from high school and college students who have participated in the program every ... and YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... or without a referral to new patients from Burnaby, BC. Patients in need ... full mouth reconstruction services, can see the esteemed team at Wall Centre Dental. ...
(Date:3/29/2017)... MINNETONKA, Minn. (PRWEB) , ... March 29, 2017 ... ... of medical office buildings (MOBs) and other outpatient facilities, and who are the ... look exclusively at those questions, Revista and Healthcare Real Estate Insights (HREI) found ...
(Date:3/29/2017)... Ca (PRWEB) , ... March 29, 2017 , ... ... process in many scientific laboratories. The assembly protocols involve many repetitive steps and ... suited for automation, which enables the high-throughput needed, and results in a lower ...
Breaking Medicine News(10 mins):